ReviewHuman vaccines & immunotherapeutics2022
Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.
Review in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Allicin-loaded soluplus polymeric micelles differentially modulate doxorubicin response in adenocarcinoma and myocardial cell models.Scientific reports · 2026Article
- Immune Efficacy of a Vaccine Candidate Based on Binding Protein 26 (BP26) from Brucella melitensis Encapsulated in Niosome Nanoparticles Against Brucellosis.Pharmaceutical research · 2026Article
- Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Peptide Modulation Overrides Glycan Synergy in Gold Nanoparticle-Based Vaccines for Cancer Immunotherapy.Cancer medicine · 2025Article
- Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches.Signal transduction and targeted therapy · 2025Review
- Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.Vaccines · 2025Review
- Unleashing the Potential of Metal Ions in cGAS-STING Activation: Advancing Nanomaterial-Based Tumor Immunotherapy.ACS omega · 2025Review
- Nanovaccines against Cervical Cancer: Reliable Strategies to Circumvent Limitations of Traditional Therapeutic Vaccines.Advanced pharmaceutical bulletin · 2025Review
- Review
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- Review
- Mapping the Nanotechnology Patent Landscape in the Field of Cancer.Recent patents on nanotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An attractive type of cancer immunotherapy is cancer therapeutic vaccines that induce antitumor immunity effectively. Although supportive results in the recent vaccine studies, there are still numerous drawbacks, such as poor stability, weak immunogenicity and strong toxicity, to be tackled for promoting the potency and durability of antitumor efficacy. NPs (Nanoparticles)-based vaccines offer unique opportunities to breakthrough the current bottleneck. As a rule, nanovaccines are new the generations of vaccines that use NPs as carriers and/or adjuvants. Several advantages of nanovaccines are constantly explored, including optimal nanometer size, high stability, plenty of antigen loading, enhanced immunogenicity, tunable antigen presentation, more retention in lymph nodes and promote patient compliance by a lower frequency of dosing. Here, we summarized the merits and highlight the diverse role nanovaccines play in improving antitumor responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.